Pasar al contenido principal

Estudio de los mecanismos moleculares que regulan la metastasis del melanoma. Implicaciones terapeúticas y búsqueda de nuevos Biomarcadores.

RYC2018-024004-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAC1 induces nuclear alterations through the LINC complex to enhance melanoma invasiveness

  • Colón-Bolea, Paula
  • García-Gómez, Rocío
  • Shackleton, Sue
  • Crespo, Piero
  • Bustelo, Xosé R.
  • Casar, Berta
© 2020 Colón-Bolea et al., RHO GTPases are key regulators of the cytoskeletal architecture, which impact a broad range of biological processes in malignant cells including motility, invasion, and metastasis, thereby affecting tumor progression. One of the constraints during cell migration is the diameter of the pores through which cells pass. In this respect, the size and shape of the nucleus pose a major limitation. Therefore, enhanced nuclear plasticity can promote cell migration. Nuclear morphology is determined in part through the cytoskeleton, which connects to the nucleoskeleton through the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex. Here, we unravel the role of RAC1 as an orchestrator of nuclear morphology in melanoma cells. We demonstrate that activated RAC1 promotes nuclear alterations through its effector PAK1 and the tubulin cytoskeleton, thereby enhancing migration and intravasation of melanoma cells. Disruption of the LINC complex prevented RAC1-induced nuclear alterations and the invasive properties of melanoma cells. Thus, RAC1 induces nuclear morphology alterations through microtubules and the LINC complex to promote an invasive phenotype in melanoma cells., B.C.’s laboratory is supported by a Retos Jóvenes Investigadores grant SAF2015-73364-JIN Ministerio de Ciencia, Innovación y Universidades (MICIU/AEI/FEDER, UE), a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)—MCIU, and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I). P.C is supported by grant SAF-2015 63638R (MINECO/FEDER, UE); by Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC), RD/12/0036/0033, and by Asociación Española Contra el Cáncer (AECC) grant GCB141423113. X.R.B. is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), MINECO (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and AECC (GC16173472GARC). Spanish funding to B.C., P.C., and X.R.B. is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination

  • García-Ibáñez, Yaiza
  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
  • Casar, Berta
  • Crespo, Piero
© 2020 by the authors., RAS mutations are the second most common genetic alteration in thyroid tumors. However, the extent to which they are associated with the most aggressive phenotypes is still controversial. Regarding their malignancy, the majority of RAS mutant tumors are classified as undetermined, which complicates their clinical management and can lead to undesired under- or overtreatment. Using the chick embryo spontaneous metastasis model, we herein demonstrate that the aggressiveness of HRAS-transformed thyroid cells, as determined by the ability to extravasate and metastasize at distant organs, is orchestrated by HRAS subcellular localization. Remarkably, aggressiveness inversely correlates with tumor size. In this respect, we also show that RAS site-specific capacity to regulate tumor growth and dissemination is dependent on VEGF-B secretion. Furthermore, we have identified the acyl protein thioesterase APT-1 as a determinant of thyroid tumor growth versus dissemination. We show that alterations in APT-1 expression levels can dramatically affect the behavior of thyroid tumors, based on its role as a regulator of HRAS sublocalization at distinct plasma membrane microdomains. In agreement, APT-1 emerges in thyroid cancer clinical samples as a prognostic factor. As such, APT-1 levels could serve as a biomarker that could help in the stratification of HRAS mutant thyroid tumors based on their aggressiveness., PC lab is supported by grant RTI2018-096658B-100 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE). Santisteban, Riesco and Crespo Laboratories are supported jointly by grants from Asociación Española Contra el Cancer (AECC; GCB141423113) and CIBERONC from the Instituto de Salud Carlos III (ISCIII). PS acknowledges support from: SAF2016-75531-R (MINECO/FEDER, UE); B2017/BMD-3724 Tironet2 (Comunidad de Madrid) and PID2019-105303RB-I00/AEI/10.13039/501100011033 from Ministerio de Ciencia e Innovación (MICIN). B.C is funded by Retos Jóvenes Investigadores grant SAF2015-73364-JIN (MICIU/AEI/FEDER, UE), a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)- MICIU and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Extending the applicability of In Ovo and Ex Ovo chicken chorioallantoic membrane assays to study cytostatic activity in neuroblastoma cells

  • Merlos Rodrigo, Miguel Angel
  • Casar, Berta
  • Michalkova, Hana
  • Jiménez Jiménez, Ana María
  • Heger, Zbynek
  • Adam, Vojtech
[Purpose]: The chick chorioallantoic membrane (CAM) assay can provide an alternative versatile, cost-effective, and ethically less controversial in vivo model for reliable screening of drugs. In the presented work, we demonstrate that CAM assay (in ovo and ex ovo) can be simply employed to delineate the effects of cisplatin (CDDP) and ellipticine (Elli) on neuroblastoma (Nbl) cells in terms of their growth and metastatic potential. [Methods]: The Nbl UKF-NB-4 cell line was established from recurrent bone marrow metastases of high-risk Nbl (stage IV, MYCN amplification, 7q21 gain). Ex ovo and in ovo CAM assays were optimized to evaluate the antimetastatic activity of CDDP and Elli. Immunohistochemistry, qRT-PCR, and DNA isolation were performed. [Results]: Ex ovo CAM assay was employed to study whether CDDP and Elli exhibit any inhibitory effects on growth of Nbl xenograft in ex ovo CAM assay. Under the optimal conditions, Elli and CDDP exhibited significant inhibition of the size of the primary tumor. To study the efficiency of CDDP and Elli to inhibit primary Nbl tumor growth, intravasation, and extravasation in the organs, we adapted the in ovo CAM assay protocol. In in ovo CAM assay, both studied compounds (CDDP and Elli) exhibited significant (p < 0.001) inhibitory activity against extravasation to all investigated organs including distal CAM. [Conclusions]: Taken together, CAM assay could be a helpful and highly efficient in vivo approach for high-throughput screening of libraries of compounds with expected anticancer activities., The authors acknowledge funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement No. 759585), the Czech Science Foundation (project no. 19-13766J), FEBS - Federation of European Biochemical Societies, and under the CEITEC 2020 project (LQ1601) by the Ministry of Education, Youth and Sports of the Czech Republic. BC is funded by Ramón y Cajal Research Program Ministry of Science and Innovation of Spain (MICIN, RYC2018-024004-I).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Scaffold coupling: ERK activation by transphosphorylation across different scaffold protein species

  • Martín-Vega, Ana
  • García-Gómez, Rocío
  • Herrero, Ana
  • Fuente-Vivas, Dalia de la
  • Parvathaneni, Swetha
  • Caloto, Rubén
  • Morante, Marta
  • Kriegsheim, Alex von
  • Bustelo, Xosé R.
  • Sacks, David B.
  • Casar, Berta
  • Crespo, Piero
RAS-ERK (extracellular signal–regulated kinase) pathway signals are modulated by scaffold proteins that assemble the components of different kinase tiers into a sequential phosphorylation cascade. In the prevailing model scaffold proteins function as isolated entities, where the flux of phosphorylation events progresses downstream linearly, to achieve ERK phosphorylation. We show that different types of scaffold proteins, specifically KSR1 (kinase suppressor of Ras 1) and IQGAP1 (IQ motif-containing guanosine triphosphatase activating protein 1), can bind to each other, forming a complex whereby phosphorylation reactions occur across both species. MEK (mitogen-activated protein kinase kinase) bound to IQGAP1 can phosphorylate ERK docked at KSR1, a process that we have named “trans-phosphorylation.” We also reveal that ERK trans-phosphorylation participates in KSR1-regulated adipogenesis, and it also underlies the modest cytotoxicity exhibited by KSR-directed inhibitors. Overall, we identify interactions between scaffold proteins and trans-phosphorylation as an additional level of regulation in the ERK cascade, with broad implications in signaling and the design of scaffold protein–aimed therapeutics., P.C. laboratory is supported by grant RTI2018-096658B-100 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE), a grant from Asociación Española Contra el Cancer (AECC; GCB141423113), and CIBERONC from the Instituto de Salud Carlos III (ISCIII). B.C. is funded by PID2020-112760RB-100 from MICIU, FERO 2021.03, a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)–MICIU, and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I). X.R.B. is funded by “la Caixa” Banking Foundation (HR20-00164), the Castilla-León autonomous government (CSI252P18, CSI145P20, and CLC-2017-01), the MSI (RTI2018-096481-B-100), and the Asociación Española Contra el Cancer (GC16173472GARC). D.B.S. is supported by NIH Intramural Research Program. A.v.K. is supported by the Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z).